**Question:** Single lesion leprosy treatment

**Core Concept:** Leprosy is a chronic infectious disease primarily caused by Mycobacterium leprae or M. leprae, which primarily affects the skin, peripheral nerves, and mucous membranes. The World Health Organization (WHO) has recommended a standardized treatment regimen for multi-bacillary (MB) leprosy and pauci-bacillary (PB) leprosy.

**Why the Correct Answer is Right:**

For single lesions in leprosy, the recommended treatment is a combination of two drugs:

1. **Dapsone (DDS):** Dapsone is an antibiotic that inhibits the growth of M. leprae by interfering with DNA synthesis and reducing the production of dioxygen, which leads to the inhibition of bacterial growth. It is a cornerstone of leprosy treatment.
2. **Clofazimine (CZ):** Clofazimine is a lipid-soluble antibiotic with anti-microbial activity against M. leprae and M. lepromatosis. It is also believed to contribute to the immunomodulatory effects on the host immune response against the bacilli, thus improving the clinical outcomes.

**Why Each Wrong Option is Incorrect:**

A. **Option A (rifampicin):** Rifampicin is an antibiotic that inhibits bacterial RNA polymerase, leading to the inhibition of DNA synthesis and bacterial growth. However, rifampicin is not part of the standard treatment for single lesion leprosy as it is not effective against M. leprae.

B. **Option B (doxycycline):** Doxycycline is a tetracycline antibiotic with anti-microbial activity against M. leprae and M. lepromatosis. However, it is not part of the standardized treatment for single lesion leprosy.

C. **Option C (thioridazine):** Thioridazine is an antipsychotic drug primarily used in psychiatry, not in leprosy treatment. It is not an antimicrobial agent and does not target M. leprae.

D. **Option D (ethambutol):** Ethambutol is an antituberculosis drug that inhibits mycolic acid synthesis in the bacterial cell wall, impairing cell growth and function. Although it has anti-mycobacterial activity, it is not a part of the standardized treatment for single lesion leprosy.

**Clinical Pearl:** In single lesion leprosy, the primary goal of therapy is to prevent further bacillary multiplication and to prevent the development of multi-bacillary disease. The correct combination therapy helps to achieve this goal, while the wrong choices do not target M. leprae directly or are unrelated to the treatment of leprosy.